Libroxar (Buprenorphine, Naloxone)

Libroxar, a buprenorphine/naloxone combination, is used within the opioid dependence treatment pathway to manage opioid use disorder.

• Opioid dependence: reduces cravings and withdrawal symptoms, supporting long‑term abstinence and facilitating psychosocial rehabilitation.
• Opioid use disorder maintenance therapy: provides stable μ‑opioid receptor activation to prevent relapse while minimizing euphoric effects.
• Opioid withdrawal management: alleviates acute withdrawal signs during the induction phase, allowing a smoother transition to maintenance dosing.

• Buprenorphine binds with high affinity to μ‑opioid receptors as a partial agonist, delivering modest analgesia and suppressing withdrawal while limiting maximal opioid effect; it also antagonizes κ‑opioid receptors, which may lessen dysphoria. Naloxone, poorly absorbed sublingually, acts as an opioid receptor antagonist; if the product is injected, naloxone rapidly blocks opioid activity, deterring misuse.

Libroxar may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset that may resolve with continued therapy.
• Headache: transient cranial pain often improving over time.
• Constipation: reduced bowel movements, manageable with diet or laxatives.
• Sweating: increased perspiration, especially during early treatment.

Serious or Rare Side Effects

• Respiratory depression: slowed breathing that can be life‑threatening, requiring immediate medical attention.
• Severe hypotension: marked drop in blood pressure, potentially causing dizziness or fainting.
• Hepatotoxicity: liver enzyme elevations or injury, monitored through laboratory tests.

When prescribing Libroxar, clinicians should consider several precautionary measures to ensure safe use.

• Assess opioid dependence severity: evaluate patient history and current opioid use before initiating therapy.
• Monitor for respiratory function: observe breathing, especially during dose adjustments or when combined with CNS depressants.
• Avoid use in acute severe asthma: risk of bronchospasm may be heightened.
• Counsel on misuse potential: educate patients about the naloxone component and the importance of sublingual administration only.
• Pregnancy and lactation: weigh benefits against risks; use only if clearly needed.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Libroxar can interact with other medicines; understanding the interaction level guides clinical decisions.

Major Interactions (Avoid)

• Benzodiazepines: combined CNS depression may cause profound respiratory depression.
• Alcohol: additive sedative effects increase risk of overdose.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise buprenorphine levels, leading to toxicity.

Moderate Interactions (Monitor Closely)

• Opioid analgesics: may diminish naloxone’s deterrent effect and increase opioid load.
• CNS depressants (e.g., gabapentin, pregabalin): monitor for enhanced sedation.
• Rifampin: induces metabolism, potentially reducing buprenorphine efficacy.